Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands

View original at globenewswire.com
Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands NEW YORK, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Approximately 12.4% of U.S. adults report taking GLP-1 medications for weight loss, more than double the rate measured in early 2024

    80% confidence

  • The wholesale acquisition cost for Wegovy is approximately $1,349 per month

    80% confidence

  • Wegovy accessed through Ro platform is sourced through NovoCare Pharmacy, which is operated by Novo Nordisk, providing authentic, FDA-approved Wegovy

    80% confidence

  • Oral formulation requires specific administration protocols, including being taken on an empty stomach with a small amount of water, with a 30-minute wait before eating, drinking, or taking other oral medications

    80% confidence

  • Cash-pay Wegovy pricing begins at $199 per month for certain starter doses during a limited promotional period through March 31, 2026

    80% confidence

  • Ro cannot coordinate coverage for Medicare, Medicaid, or VA plans for GLP-1 medications used for weight loss

    80% confidence

  • It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, though semaglutide caused thyroid tumors in rodent studies

    80% confidence

  • Oral Wegovy contains the same active ingredient (semaglutide) as injectable Wegovy and demonstrated weight loss outcomes in clinical trials

    80% confidence

  • Compounded versions of semaglutide are not reviewed or approved as finished products for safety, effectiveness, or quality

    80% confidence

  • Results from oral semaglutide trials were considered comparable to injectable formulation trials, though the studies were conducted separately

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands — Source | Via News | Finance Via News